Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 57 29 6 17
Adverse Event Associated with Cardiac Arrhythmia 70
Premature Cardiac Complex 70
Cardiac Arrhythmias 6
Extrasystoles 57

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant


HPO:

31
cardiac arrhythmia:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM® 57 115000
ICD10 32 I49.8 I49.9
MedGen 41 C0003811
SNOMED-CT via HPO 68 263681008 26636000 88425004
UMLS 70 C0340464 C1560249

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to cardiac arrhythmia, ankyrin-b-related and arrhythmogenic right ventricular dysplasia, familial, 8, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Developmental Biology and Cardiac conduction. The drugs Moxifloxacin and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and lung, and related phenotypes are abnormality of the nervous system and sudden death

More information from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 592)
# Related Disease Score Top Affiliating Genes
1 cardiac arrhythmia, ankyrin-b-related 32.3 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 CACNA1C
2 arrhythmogenic right ventricular dysplasia, familial, 8 31.8 RYR2 PKP2 DSP
3 long qt syndrome 11 31.7 KCNQ1 KCNE2 CACNA1C ANK2
4 long qt syndrome 14 31.7 SCN5A KCNQ1 KCNH2 CACNA1C
5 long qt syndrome 12 31.7 SCN5A KCNQ1 KCNH2 KCNE2 ANK2
6 long qt syndrome 13 31.7 SCN5A KCNQ1 KCNH2 KCNE2 ANK2
7 long qt syndrome 15 31.6 SCN1B CACNA1C
8 ventricular fibrillation, paroxysmal familial, 1 31.5 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 DSP
9 long qt syndrome 5 31.5 SCN5A KCNQ1 KCNH2 KCNE2 CACNA1C ANK2
10 long qt syndrome 9 31.4 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 CACNA1C
11 andersen cardiodysrhythmic periodic paralysis 31.3 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 CACNA1C
12 syncope 31.0 SCN5A RYR2 KCNQ1 KCNH2
13 progressive familial heart block, type ia 30.8 SCN5A DSP ANK2
14 congestive heart failure 30.7 SCN5A RYR2 KCNQ1 CACNA1C
15 cardiac conduction defect 30.7 SCN5A SCN1B RYR2 KCNQ1 DSP CACNA1C
16 cardiac arrest 30.7 SCN5A RYR2 KCNQ1 KCNH2 DSP ANK2
17 atrioventricular block 30.6 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 CACNA1C
18 brugada syndrome 4 30.6 SCN5A KCNQ1 KCNH2 CACNA1C
19 atrial fibrillation 30.6 SCN5A SCN3B SCN1B RYR2 KCNQ1 KCNH2
20 brugada syndrome 3 30.6 KCNE2 CACNA1C-AS1 CACNA1C ANK2
21 first-degree atrioventricular block 30.5 SCN5A KCNH2
22 familial short qt syndrome 30.5 KCNQ1 KCNH2
23 idiopathic ventricular fibrillation, non brugada type 30.5 SCN5A RYR2 CACNA1C
24 brugada syndrome 5 30.4 SCN5A SCN1B
25 left bundle branch hemiblock 30.4 SCN5A RYR2 PKP2 DSP
26 sick sinus syndrome 1 30.2 SCN5A LOC110121269
27 third-degree atrioventricular block 30.2 SCN5A SCN1B KCNH2
28 noonan syndrome with multiple lentigines 30.0 SCN5A RYR2 KCNQ1 KCNH2
29 brugada syndrome 1 30.0 SCN5A RYR2 LOC110121269 KCNH2
30 atrial standstill 1 29.9 SCN5A SCN1B RYR2 PKP2 DSP
31 cardiomyopathy, familial hypertrophic, 1 29.8 SCN5A RYR2 KCNH2 CACNA1C
32 familial long qt syndrome 29.8 SCN5A LOC110121269 KCNQ1OT1 KCNQ1-AS1 KCNQ1 KCNH2
33 arrhythmogenic right ventricular cardiomyopathy 29.8 SCN5A RYR2 PKP2 KCNH2 DSP CACNA1C
34 heart disease 29.8 SCN5A RYR2 PKP2 KCNQ1 KCNH2 KCNE2
35 long qt syndrome 6 29.7 SCN5A KCNQ1 KCNH2 KCNE2 CACNA1C ANK2
36 chromosome 2q35 duplication syndrome 29.7 KCNQ1 KCNH2 CACNA1C
37 second-degree atrioventricular block 29.6 SCN5A SCN3B
38 lipoprotein quantitative trait locus 29.5 SCN5A RYR2 PKP2 KCNQ1 KCNH2 KCNE2
39 short qt syndrome 29.5 SCN5A RYR2 KCNQ1OT1 KCNQ1-AS1 KCNQ1 KCNH2
40 sick sinus syndrome 29.5 SCN5A SCN3B SCN1B RANGRF LOC110121269 CACNA1C
41 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 29.4 SCN5A RYR2 PKP2 KCNQ1 KCNH2 DTNA
42 timothy syndrome 29.3 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 CACNA1C-AS1
43 hypertrophic cardiomyopathy 29.3 SCN5A RYR2 PKP2 KCNQ1 KCNH2 KCNE2
44 sudden infant death syndrome 29.2 SCN5A SCN3B SCN1B RYR2 LOC110121269 KCNQ1
45 dilated cardiomyopathy 29.2 SCN5A RYR2 PKP2 KCNQ1 KCNH2 KCNE2
46 early infantile epileptic encephalopathy 29.2 SCN5A SCN3B SCN1B KCNQ1 KCNH2 CACNA1C
47 jervell and lange-nielsen syndrome 1 29.1 SCN5A KCNQ1OT1 KCNQ1-AS1 KCNQ1 KCNH2 KCNE2
48 long qt syndrome 3 29.1 SCN5A SCN3B SCN1B RYR2 LOC110121269 KCNQ1
49 right bundle branch block 29.0 SCN5A SCN3B SCN1B RANGRF PKP2 KCNH2
50 sinoatrial node disease 29.0 SCN5A SCN3B SCN1B RYR2 RANGRF KCNQ1

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation First-Degree Atrioventricular Block
Heart Disease Hypertension, Essential
Intermediate Coronary Syndrome Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Human phenotypes related to Cardiac Arrhythmia:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707
2 sudden death 31 HP:0001699
3 polymorphic and polytopic ventricular extrasystoles 31 HP:0006696

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Neuro:
syncopal attacks

Misc:
sudden death

Clinical features from OMIM®:

115000 (Updated 20-May-2021)

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus; bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 CACNA1C CAPN3 DSP DTNA GNB5 KCNH2
2 muscle MP:0005369 9.36 CACNA1C CAPN3 DSP DTNA GNB5 KCNH2

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
4
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
5
Flecainide Approved, Withdrawn Phase 4 54143-55-4 3356
6
Ajmaline Approved, Experimental Phase 4 4360-12-7 441080
7
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
8
Procainamide Approved Phase 4 51-06-9 4913
9
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
10
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
11 Anti-Bacterial Agents Phase 4
12 Norgestimate, ethinyl estradiol drug combination Phase 4
13 Anesthetics, General Phase 4
14 Narcotics Phase 4
15 Anesthetics, Intravenous Phase 4
16 Analgesics, Opioid Phase 4
17 Anesthetics Phase 4
18 Adrenergic alpha-Agonists Phase 4
19 Adrenergic Agonists Phase 4
20 Adrenergic Agents Phase 4
21 Neurotransmitter Agents Phase 4
22 Analgesics Phase 4
23 Sodium Channel Blockers Phase 4
24 Anti-Arrhythmia Agents Phase 4
25 Diuretics, Potassium Sparing Phase 4
26 Hypnotics and Sedatives Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Calcium, Dietary Phase 4
29 Vasodilator Agents Phase 4
30 Cytochrome P-450 CYP3A Inhibitors Phase 4
31 Potassium Channel Blockers Phase 4
32 Hormones Phase 4
33 Anticonvulsants Phase 4
34 Tocolytic Agents Phase 4
35 calcium channel blockers Phase 4
36 Cytochrome P-450 Enzyme Inhibitors Phase 4
37
Calcium Nutraceutical Phase 4 7440-70-2 271
38
Galantamine Approved Phase 3 357-70-0 9651
39
Moricizine Approved, Investigational, Withdrawn Phase 3 31883-05-3 34633
40
Encainide Approved, Investigational, Withdrawn Phase 3 66778-36-7 48033 48041
41
Ranolazine Approved, Investigational Phase 3 95635-55-5, 142387-99-3 56959
42
Warfarin Approved Phase 3 81-81-2 6691 54678486
43
Dalteparin Approved Phase 3 9005-49-6
44
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
45
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
46 Cholinesterase Inhibitors Phase 3
47 Cholinergic Agents Phase 3
48 Nootropic Agents Phase 3
49 Trace Elements Phase 3
50 Micronutrients Phase 3

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 Genetics of QT Response to Moxifloxacin Unknown status NCT01936480 Phase 4 Moxifloxacin 400mg once time;Placebo
2 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
3 Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics: a Double-blind "Split-mouth" Controlled Trial. Completed NCT01719978 Phase 4 3.6mL 2% Mepivacaine with 1:100,000 epinephrine;Hyaluronidase;Placebo
4 CRYptogenic STroke And underLying AF Trial Completed NCT00924638 Phase 4
5 Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Completed NCT00702117 Phase 4 flecainide;ajmaline;procainamide
6 Multicenter Study for the Prevention of Post-Operative Cardiac Arrhythmias Not yet recruiting NCT04234906 Phase 4 Dexmedetomidine;Magnesium Sulfate;Amiodarone;Procainamide
7 Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: A Cardiac Safety Study. Completed NCT00309725 Phase 3 galantamine
8 Influence of a Specific Micronutrient Combination on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia Completed NCT02652338 Phase 3
9 Cardiac Arrhythmia Suppression Trial (CAST) Completed NCT00000526 Phase 3 encainide;flecainide;moricizine
10 The Effect of Ranolazine on Cardiac Arrhythmias and Microvolt T- Wave Alternans in Patients With Significant Left Ventricular Dysfunction Completed NCT00998218 Phase 3 Ranolazine;Placebo
11 An Open-Label Randomized Control Trial of Pre-Operative Low Molecular Weight Heparin Versus Tapered Warfarin as Bridging Therapy for Patients With Implantation of Pacemaker or Defibrillator Terminated NCT02094157 Phase 3 Tapered warfarin regimen;Bridged regimen Low-molecular-weight heparin
12 Remote Intracardiac Catheter Target Acquisition Using the Magnetecs Catheter Guidance Control and Imaging (CGCI) System Unknown status NCT01222156 Phase 1, Phase 2
13 Sleep in Cardiac Patients With Implantable Cardioverter Defibrillators (ICD) Completed NCT02232204 Phase 2
14 Patient and Intimate Partner Intervention to Improve Outcomes After an ICD Completed NCT01252615 Phase 2
15 A Randomized, Placebo-controlled, Dose-range Finding Study to Assess the Pharmacokinetic and Pharmacodynamic Parameters, Safety, Tolerability, and Immunogenicity of MAA868 in Patients With Atrial Fibrillation Completed NCT04213807 Phase 2
16 Cardiac Arrhythmia Pilot Study (CAPS) Completed NCT00000504 Phase 2 encainide;moricizine;flecainide;imipramine
17 Cardiac Arrhythmia Catheter Ablation Procedures Guided by x-Ray Imaging: N-Acetylcysteine Protection Against Radiation Induced Cellular damagE (CARAPACE Study) Recruiting NCT04154982 Phase 2 Acetyl cysteine
18 Clinical Evaluation of the CARTO™ XP EP Navigation System v9 and Biosense Webster SOUNDSTAR 3D Diagnostic Ultrasound. A Feasibility Study Withdrawn NCT00449085 Phase 2
19 STTR Phase II : Skin Sympathetic Nerve Activity and Cardiac Arrhythmias Withdrawn NCT02939469 Phase 2
20 Occurrence of Heart Arrhythmia During Restorative Dental Procedure Under Local Anesthesia , in Heart Failure Pacients. A Double-blind Study Unknown status NCT02228083 Lidocaine with epinephrine
21 Observational Study of the Sleuth Implantable ECG Monitoring System Unknown status NCT00717106
22 Pilot Clinical Study of the Sleuth Implantable ECG Monitoring System Unknown status NCT00719277
23 European Pediatric Catheter Ablation Registry Unknown status NCT01691573
24 ENHANCED Device Programming to Reduce Therapies and Improve Quality of Life in Implantable Cardioverter Defibrillator Patients: A Prospective, Single-arm Safety Monitoring Study (ENHANCED-ICD Study) Unknown status NCT01715116
25 A Prospective Randomized Study on the Effect of Oesophageal Temperature Monitoring on the Incidence of Esophageal Lesions After Left Atrial Ablation for the Treatment of Atrial Fibrillation. Unknown status NCT03645070
26 Documentation of Cardiac Arrhythmias After Open Heart Surgery Unknown status NCT02657590
27 Optimizing Diagnostics And Therapy Of Arrhythmia And Syncope Events Using Intelligent Telemetric Solutions. Diagnostics Of Syncope In Children. Unknown status NCT01265290
28 Use of the Rhytmia System for Determining the Precise Location and Potential Mechanism of Premature Ventricular Contractions Unknown status NCT03460535
29 Same Day Discharge Unknown status NCT02943512
30 Metabolism of Patients With Genetically Caused Cardiac Arrhythmia Unknown status NCT02775513
31 Risk Assessment of Cardiac ARrhythmias in Patients With MYocarditis Unknown status NCT03801681
32 Identification of Predictors of Cardiac Arrhythmias and Sudden Death in Pediatric Patients Affected With Laminopathies Unknown status NCT02601066
33 Effect of High-dose Caffeine on Cardiac Arrhythmias in Patients With Heart Failure - a Randomized Clinical Trial Unknown status NCT02045992
34 Effects of Endurance Training on Patients With Reduced LVEF and Cardiac Resynchronisation Therapy Especially for Cardiac Arrhythmias Unknown status NCT00472238
35 Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias Unknown status NCT03631303
36 Development of a Novel Convolution Neural Network for Arrhythmia Classification for Shockable Cardiac Rhythms Completed NCT03662802
37 Esophageal 3D Mapping System for Cardiac Arrhythmias: Pilot Study to Establish Basis for Improved Arrhythmia Diagnostics Using the esoECG-3D Catheter Completed NCT03365440
38 The Comparison of Serum Potassium Concentration, Antiarrhythmic Effect, and Myocardial Protective Effect Between Dexmedetomidine and Remifentanil Infusion in Patients Undergoing Coronary Artery Bypass Surgery Completed NCT01572454 Dexmedetomidine infusion;Remifentanil infusion
39 MRI Assessment of Arrythmia Ablation Lesions Completed NCT02761343
40 Evaluating Myocardial Injury During ICD Implantation Using the Upper Limit of Vulnerability (ULV) Method vs. Standard Defibrillation Threshold Testing Completed NCT02111993
41 Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk Individuals. Completed NCT02036450
42 Prospective Registry on User Experience With The Mapping System For Ablation Procedures Completed NCT02698670
43 EnSite Precision™ Cardiac Mapping System and EnSite Precision™ Software v2.0 Observational Registry Completed NCT02757430
44 Electroanatomical Mapping of Patients Undergoing Catheter Ablation Procedures Using Rhythmia Mapping System and Catheter Completed NCT01642537
45 The Efficacy of Adapted Yoga in Managing Psychosocial Risk in Implantable Cardioverter Defibrillator (ICD) Patients Completed NCT01716351
46 Correlations Between Arrhythmias, Climatic Variables and Air Pollution in Patients With Pacemaker and ICD, Followed by Remote Monitoring. Completed NCT01723761
47 The Circadian Rhythm of Potassium and Cystatin c and the Day-to-day Variability Completed NCT01318746
48 Electrical Signal Collection From a 20 Pole Catheter During Routine Cardiac Procedures Completed NCT02326519
49 FREEDOM - A Frequent Optimization Study Using the QuickOpt Method Completed NCT00418314
50 Long Term Monitoring to Detect Risk of Sudden Death in Inherited Arrhythmia Patients Completed NCT04124237

Search NIH Clinical Center for Cardiac Arrhythmia

Genetic Tests for Cardiac Arrhythmia

Genetic tests related to Cardiac Arrhythmia:

# Genetic test Affiliating Genes
1 Cardiac Arrhythmia 29

Anatomical Context for Cardiac Arrhythmia

MalaCards organs/tissues related to Cardiac Arrhythmia:

40
Heart, Liver, Lung, Kidney, Brain, Thyroid, Skin

Publications for Cardiac Arrhythmia

Articles related to Cardiac Arrhythmia:

(show top 50) (show all 5897)
# Title Authors PMID Year
1
Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations. 6 61
26805781 2016
2
Association of Genetic and Clinical Aspects of Congenital Long QT Syndrome With Life-Threatening Arrhythmias in Japanese Patients. 6
30758498 2019
3
SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. 6
30059973 2018
4
Even pore-localizing missense variants at highly conserved sites in KCNQ1-encoded Kv7.1 channels may have wild-type function and not cause type 1 long QT syndrome: Do not rely solely on the genetic test company's interpretation. 6
29876285 2018
5
Impact of Ancestral Differences and Reassessment of the Classification of Previously Reported Pathogenic Variants in Patients With Brugada Syndrome in the Genomic Era: A SADS-TW BrS Registry. 6
30662450 2018
6
Exploring digenic inheritance in arrhythmogenic cardiomyopathy. 6
29221435 2017
7
Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. 6
28527814 2017
8
Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. 6
28097316 2017
9
Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. 6
27532257 2017
10
Postmortem genetic screening for the identification, verification, and reporting of genetic variants contributing to the sudden death of the young. 6
27435932 2016
11
Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. 6
25820315 2015
12
Maturation-Based Model of Arrhythmogenic Right Ventricular Dysplasia Using Patient-Specific Induced Pluripotent Stem Cells. 6
25971409 2015
13
The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. 6
24503780 2014
14
Truncating plakophilin-2 mutations in arrhythmogenic cardiomyopathy are associated with protein haploinsufficiency in both myocardium and epidermis. 6
24704780 2014
15
Reply: The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: more questions than answers? 6
24768880 2014
16
Position of premature termination codons determines susceptibility of hERG mutations to nonsense-mediated mRNA decay in long QT syndrome. 6
24530480 2014
17
Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratification of perinatal long-QT syndrome. 6
23995044 2013
18
Results of genetic testing in 855 consecutive unrelated patients referred for long QT syndrome in a clinical laboratory. 6
23631430 2013
19
Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. 6
23354045 2013
20
Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. 6
24223155 2013
21
The diagnostic and therapeutic aspects of loss-of-function cardiac sodium channelopathies in children. 6
22885917 2012
22
Clinical phenotype and diagnosis of arrhythmogenic right ventricular cardiomyopathy in pediatric patients carrying desmosomal gene mutations. 6
21723241 2011
23
Recurrent and founder mutations in the Netherlands : Plakophilin-2 p.Arg79X mutation causing arrhythmogenic right ventricular cardiomyopathy/dysplasia. 6
21301620 2010
24
Shared desmosome gene findings in early and late onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. 6
20857253 2010
25
The p.A897KfsX4 frameshift variation in desmocollin-2 is not a causative mutation in arrhythmogenic right ventricular cardiomyopathy. 6
20197793 2010
26
Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. 6
20152563 2010
27
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. 6
20129283 2010
28
The genetic basis of long QT and short QT syndromes: a mutation update. 6
19862833 2009
29
Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. 6
19841300 2009
30
Prevalence of the congenital long-QT syndrome. 6
19841298 2009
31
Comprehensive desmosome mutation analysis in north americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy. 6
20031617 2009
32
Desmoglein-2 and desmocollin-2 mutations in dutch arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results from a multicenter study. 6
20031616 2009
33
Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. 6
19716085 2009
34
Characterization of the molecular phenotype of two arrhythmogenic right ventricular cardiomyopathy (ARVC)-related plakophilin-2 (PKP2) mutations. 6
19084810 2008
35
Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. 6
17010805 2006
36
Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy. 6
16917092 2006
37
Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. 6
16549640 2006
38
Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. 6
16567567 2006
39
KCNQ1 mutations in patients with a family history of lethal cardiac arrhythmias and sudden death. 6
12702160 2003
40
Familial paroxysmal ventricular tachycardia in two sisters. 57
4129426 1974
41
Fatal familial cardiac arrhythmias. Histologic observations on the cardiac conduction system. 57
5016833 1972
42
FAMILIAL POLYTOPIC AND POLYMORPHIC EXTRASYSTOLES. 57
14115011 1964
43
The focal adhesion protein Testin modulates KCNE2 potassium channel β subunit activity. 61
33464998 2021
44
Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. 61
33598568 2021
45
Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. 61
32332235 2021
46
Diabetes and hypertension: Pivotal involvement of purinergic signaling. 61
33524787 2021
47
Mindfulness and Interoceptive Exposure Therapy for Anxiety Sensitivity in Atrial Fibrillation: A Pilot Study. 61
31550903 2021
48
ECG changes in patients with opioid use disorder; P-QT wave dispersion: a retrospective study. 61
33215556 2021
49
[Cardiac arrhythmia]. 61
33783803 2021
50
Cardiac arrhythmias associated with volume-assured pressure support mode in a patient with autonomic dysfunction and mitochondrial disease. 61
33231166 2021

Variations for Cardiac Arrhythmia

ClinVar genetic disease variations for Cardiac Arrhythmia:

6 (show top 50) (show all 1933)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SCN3B NM_018400.3(SCN3B):c.423C>G (p.Ile141Met) SNV Pathogenic 224720 rs879253730 GRCh37: 11:123513176-123513176
GRCh38: 11:123642468-123642468
2 KCNQ1 NM_000218.3(KCNQ1):c.1356del (p.Leu453fs) Deletion Pathogenic 922607 GRCh37: 11:2610046-2610046
GRCh38: 11:2588816-2588816
3 KCNQ1 NM_000218.3(KCNQ1):c.1043_1054delinsCA (p.Gly348fs) Indel Pathogenic 919956 GRCh37: 11:2606452-2606463
GRCh38: 11:2585222-2585233
4 KCNQ1 NM_000218.3(KCNQ1):c.153C>A (p.Tyr51Ter) SNV Pathogenic 933168 GRCh37: 11:2466481-2466481
GRCh38: 11:2445251-2445251
5 KCNH2 NM_172056.2(KCNH2):c.809_812delinsAAAAGC (p.Thr270fs) Indel Pathogenic 200614 rs794728426 GRCh37: 7:150655251-150655254
GRCh38: 7:150958163-150958166
6 KCNH2 NM_172056.2(KCNH2):c.853_859del (p.Ala285fs) Deletion Pathogenic 200618 rs794728428 GRCh37: 7:150655204-150655210
GRCh38: 7:150958116-150958122
7 KCNH2 NM_172056.2(KCNH2):c.1201_1204dup (p.His402fs) Duplication Pathogenic 200630 rs794728434 GRCh37: 7:150649865-150649866
GRCh38: 7:150952777-150952778
8 KCNH2 NM_000238.3(KCNH2):c.2783_2789del (p.Gly928fs) Deletion Pathogenic 200676 rs794728457 GRCh37: 7:150644870-150644876
GRCh38: 7:150947782-150947788
9 KCNH2 NM_000238.4(KCNH2):c.2966-2_2967dup Duplication Pathogenic 200691 rs794728464 GRCh37: 7:150644600-150644601
GRCh38: 7:150947512-150947513
10 KCNH2 NM_000238.3(KCNH2):c.3079dup (p.Leu1027fs) Duplication Pathogenic 200695 rs794728465 GRCh37: 7:150644488-150644489
GRCh38: 7:150947400-150947401
11 KCNH2 NM_000238.3(KCNH2):c.3096_3099dup (p.Pro1034fs) Duplication Pathogenic 200699 rs794728467 GRCh37: 7:150644468-150644469
GRCh38: 7:150947380-150947381
12 KCNH2 NM_000238.3(KCNH2):c.3136del (p.Gln1046fs) Deletion Pathogenic 200709 rs794728472 GRCh37: 7:150644432-150644432
GRCh38: 7:150947344-150947344
13 KCNH2 NM_172056.2(KCNH2):c.244_252dup (p.Ile82_Gln84dup) Duplication Pathogenic 200717 rs794728476 GRCh37: 7:150671853-150671854
GRCh38: 7:150974765-150974766
14 KCNH2 NM_172056.2(KCNH2):c.373_374insGTGG (p.Phe125fs) Insertion Pathogenic 200759 rs794728489 GRCh37: 7:150656758-150656759
GRCh38: 7:150959670-150959671
15 KCNH2 NM_172056.2(KCNH2):c.1142del (p.Gly381fs) Deletion Pathogenic 200785 rs794728497 GRCh37: 7:150649928-150649928
GRCh38: 7:150952840-150952840
16 KCNH2 NM_172056.2(KCNH2):c.1815del (p.Ser606fs) Deletion Pathogenic 200789 rs794728499 GRCh37: 7:150648666-150648666
GRCh38: 7:150951578-150951578
17 KCNH2 NM_172056.2(KCNH2):c.2053del (p.Arg685fs) Deletion Pathogenic 200791 rs794728500 GRCh37: 7:150648101-150648101
GRCh38: 7:150951013-150951013
18 KCNH2 NM_172056.2(KCNH2):c.100del (p.Ala34fs) Deletion Pathogenic 200805 rs794728506 GRCh37: 7:150672006-150672006
GRCh38: 7:150974918-150974918
19 KCNH2 NM_172056.2(KCNH2):c.106del (p.Val36fs) Deletion Pathogenic 200807 rs794728507 GRCh37: 7:150672000-150672000
GRCh38: 7:150974912-150974912
20 DSP NM_004415.4(DSP):c.2528C>A (p.Ser843Ter) SNV Pathogenic 374137 rs1057518920 GRCh37: 6:7575619-7575619
GRCh38: 6:7575386-7575386
21 KCNQ1 NM_181798.1(KCNQ1):c.962del (p.Pro321fs) Deletion Pathogenic 52977 rs397508087 GRCh37: 11:2610029-2610029
GRCh38: 11:2588799-2588799
22 KCNQ1-AS1 , KCNQ1 NM_181798.1(KCNQ1):c.1461_1463del (p.His487del) Deletion Pathogenic 53020 rs397508101 GRCh37: 11:2869042-2869044
GRCh38: 11:2847812-2847814
23 KCNQ1 NM_000218.2(KCNQ1):c.165_187del (p.Gly57fs) Deletion Pathogenic 200889 rs794728563 GRCh37: 11:2466490-2466512
GRCh38: 11:2445260-2445282
24 SCN5A NM_000335.5(SCN5A):c.3595dup (p.His1199fs) Duplication Pathogenic 924057 GRCh37: 3:38616855-38616856
GRCh38: 3:38575364-38575365
25 SCN5A NM_000335.5(SCN5A):c.127C>T (p.Arg43Ter) SNV Pathogenic 924596 GRCh37: 3:38674672-38674672
GRCh38: 3:38633181-38633181
26 KCNQ1 NM_000218.3(KCNQ1):c.1330del (p.Thr444fs) Deletion Pathogenic 925351 GRCh37: 11:2610021-2610021
GRCh38: 11:2588791-2588791
27 KCNH2 NM_172056.2(KCNH2):c.735_754dup (p.Arg252fs) Duplication Pathogenic 200612 rs794728425 GRCh37: 7:150655308-150655309
GRCh38: 7:150958220-150958221
28 KCNH2 NM_000238.3(KCNH2):c.2777del (p.Pro926fs) Deletion Pathogenic 200674 rs794728456 GRCh37: 7:150644882-150644882
GRCh38: 7:150947794-150947794
29 KCNH2 NM_172057.2(KCNH2):c.2085_2092dup (p.Val698fs) Duplication Pathogenic 200705 rs794728470 GRCh37: 7:150644455-150644456
GRCh38: 7:150947367-150947368
30 KCNH2 NM_172056.2(KCNH2):c.154del (p.Cys52fs) Deletion Pathogenic 200809 rs794728508 GRCh37: 7:150671952-150671952
GRCh38: 7:150974864-150974864
31 TANGO2 NM_152906.7(TANGO2):c.460G>A (p.Gly154Arg) SNV Pathogenic 208823 rs752298579 GRCh37: 22:20049061-20049061
GRCh38: 22:20061538-20061538
32 TANGO2 NM_152906.7(TANGO2):c.146-3605_451+2245del Deletion Pathogenic 224772 GRCh37: 22:20036383-20045781
GRCh38: 22:20048860-20058258
33 CAPN3 NM_000070.3(CAPN3):c.1322del (p.Gly441fs) Deletion Pathogenic 281062 rs1555421871 GRCh37: 15:42691815-42691815
GRCh38: 15:42399617-42399617
34 SCN5A NM_000335.5(SCN5A):c.189del (p.Lys63fs) Deletion Pathogenic 928434 GRCh37: 3:38674610-38674610
GRCh38: 3:38633119-38633119
35 KCNQ1OT1 , KCNQ1 NM_000218.3(KCNQ1):c.1443_1461dup (p.Asp488fs) Duplication Pathogenic 926196 GRCh37: 11:2683236-2683237
GRCh38: 11:2662006-2662007
36 KCNH2 NM_000238.3(KCNH2):c.3096_3099dup (p.Pro1034fs) Duplication Pathogenic 200699 rs794728467 GRCh37: 7:150644468-150644469
GRCh38: 7:150947380-150947381
37 KCNH2 NM_000238.3(KCNH2):c.2892del (p.Gly965fs) Deletion Pathogenic 418247 rs794728462 GRCh37: 7:150644767-150644767
GRCh38: 7:150947679-150947679
38 PKP2 NM_004572.3(PKP2):c.14del (p.Gly5fs) Deletion Pathogenic 45027 rs397516996 GRCh37: 12:33049652-33049652
GRCh38: 12:32896718-32896718
39 PKP2 NM_004572.3(PKP2):c.2013del (p.Lys672fs) Deletion Pathogenic 202022 rs764817683 GRCh37: 12:32974422-32974422
GRCh38: 12:32821488-32821488
40 PKP2 NM_001005242.3(PKP2):c.235C>T (p.Arg79Ter) SNV Pathogenic 6754 rs121434420 GRCh37: 12:33031955-33031955
GRCh38: 12:32879021-32879021
41 PKP2 NM_001005242.3(PKP2):c.1211dup (p.Val406fs) Duplication Pathogenic 45015 rs397516989 GRCh37: 12:33003866-33003867
GRCh38: 12:32850932-32850933
42 DSP NM_004415.4(DSP):c.699G>A (p.Trp233Ter) SNV Pathogenic 44946 rs397516955 GRCh37: 6:7562986-7562986
GRCh38: 6:7562753-7562753
43 SCN5A NM_198056.2(SCN5A):c.1100G>A (p.Arg367His) SNV Pathogenic 9390 rs28937318 GRCh37: 3:38648200-38648200
GRCh38: 3:38606709-38606709
44 KCNH2 NM_172057.2(KCNH2):c.1765dup (p.Glu589fs) Duplication Pathogenic 200678 rs794728458 GRCh37: 7:150644873-150644874
GRCh38: 7:150947785-150947786
45 SCN5A NM_000335.4(SCN5A):c.2548_2549GT[3] (p.Phe851fs) Microsatellite Pathogenic 201560 rs397514450 GRCh37: 3:38627417-38627418
GRCh38: 3:38585926-38585927
46 KCNH2 NM_172057.2(KCNH2):c.1939_1940del (p.Leu647fs) Deletion Pathogenic 200693 rs748706373 GRCh37: 7:150644699-150644700
GRCh38: 7:150947611-150947612
47 KCNH2 NM_172057.2(KCNH2):c.1755dup (p.Pro586fs) Duplication Pathogenic 200672 rs794728455 GRCh37: 7:150644883-150644884
GRCh38: 7:150947795-150947796
48 KCNQ1 NM_181798.1(KCNQ1):c.481_499del (p.Val161fs) Deletion Pathogenic 53119 rs397508129 GRCh37: 11:2594153-2594171
GRCh38: 11:2572923-2572941
49 KCNQ1 NM_181798.1(KCNQ1):c.349C>T (p.Gln117Ter) SNV Pathogenic 519369 rs1554893091 GRCh37: 11:2593289-2593289
GRCh38: 11:2572059-2572059
50 SCN5A NM_198056.2(SCN5A):c.4867C>T (p.Arg1623Ter) SNV Pathogenic 9374 rs137854613 GRCh37: 3:38592996-38592996
GRCh38: 3:38551505-38551505

Expression for Cardiac Arrhythmia

Search GEO for disease gene expression data for Cardiac Arrhythmia.

Pathways for Cardiac Arrhythmia

Pathways related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 SCN5A SCN3B SCN1B PKP2 DSP CACNA1C
2
Show member pathways
12.54 SCN5A SCN3B SCN1B RYR2 RANGRF KCNQ1
3
Show member pathways
12.46 SCN5A SCN3B SCN1B GNB5 CACNA1C
4
Show member pathways
12.33 SCN5A SCN1B RYR2 KCNQ1 CACNA1C
5 12.12 KCNQ1 KCNH2 KCNE2 GNB5 CACNA1C
6 11.94 RYR2 PKP2 DSP CACNA1C
7 11.93 SCN5A SCN3B RYR2 KCNQ1 KCNH2
8
Show member pathways
11.8 SCN5A SCN3B SCN1B ANK2
9
Show member pathways
11.37 SCN5A SCN3B SCN1B RANGRF KCNQ1 KCNE2
10 11.07 SCN5A SCN3B SCN1B RYR2 KCNQ1 KCNH2
11 11.03 SCN5A SCN3B SCN1B ANK2

GO Terms for Cardiac Arrhythmia

Cellular components related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.2 SCN5A SCN3B SCN1B RYR2 RANGRF PKP2
2 sarcolemma GO:0042383 9.65 SCN5A RYR2 DTNA CACNA1C ANK2
3 Z disc GO:0030018 9.63 SCN5A SCN3B RYR2 CAPN3 CACNA1C ANK2
4 voltage-gated potassium channel complex GO:0008076 9.58 KCNQ1 KCNH2 KCNE2
5 voltage-gated sodium channel complex GO:0001518 9.54 SCN5A SCN3B SCN1B
6 T-tubule GO:0030315 9.35 SCN5A SCN1B CAPN3 CACNA1C ANK2
7 intercalated disc GO:0014704 9.1 SCN5A SCN1B RANGRF PKP2 DSP ANK2

Biological processes related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.14 SCN5A SCN3B SCN1B RYR2 KCNQ1 KCNH2
2 transmembrane transport GO:0055085 10.11 SCN5A RYR2 KCNQ1 KCNH2 CACNA1C
3 ion transmembrane transport GO:0034220 10.05 SCN5A SCN3B SCN1B RYR2 KCNH2
4 regulation of ion transmembrane transport GO:0034765 9.95 SCN5A SCN3B SCN1B KCNQ1 KCNH2 KCNE2
5 sodium ion transmembrane transport GO:0035725 9.88 SCN5A SCN3B SCN1B
6 cellular response to drug GO:0035690 9.86 KCNQ1 KCNH2 KCNE2
7 cardiac muscle contraction GO:0060048 9.85 SCN5A SCN3B SCN1B RYR2 KCNQ1 KCNH2
8 regulation of heart rate GO:0002027 9.83 SCN5A RYR2 RANGRF ANK2
9 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.8 RYR2 CACNA1C ANK2
10 positive regulation of heart rate GO:0010460 9.8 SCN3B RYR2 KCNQ1
11 positive regulation of sodium ion transport GO:0010765 9.8 SCN5A SCN3B SCN1B PKP2
12 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.8 SCN5A SCN1B KCNQ1 KCNH2 KCNE2 ANK2
13 cardiac conduction GO:0061337 9.8 SCN5A SCN3B SCN1B KCNQ1 KCNH2 KCNE2
14 membrane depolarization GO:0051899 9.79 SCN5A SCN3B SCN1B
15 regulation of sodium ion transmembrane transporter activity GO:2000649 9.79 SCN3B SCN1B RANGRF
16 membrane depolarization during action potential GO:0086010 9.78 SCN5A SCN3B KCNH2
17 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.78 SCN5A SCN3B SCN1B CACNA1C
18 potassium ion export across plasma membrane GO:0097623 9.77 KCNQ1 KCNH2 KCNE2
19 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.77 RYR2 PKP2 CACNA1C
20 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.76 KCNQ1 KCNH2 KCNE2
21 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.76 RYR2 PKP2 DSP CACNA1C
22 membrane repolarization GO:0086009 9.75 KCNQ1 KCNH2 KCNE2
23 regulation of membrane repolarization GO:0060306 9.74 KCNQ1 KCNH2 KCNE2
24 membrane repolarization during action potential GO:0086011 9.73 KCNQ1 KCNH2 KCNE2
25 atrial cardiac muscle cell action potential GO:0086014 9.73 SCN5A SCN3B KCNQ1 ANK2
26 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.72 SCN5A SCN3B SCN1B
27 regulation of potassium ion transmembrane transport GO:1901379 9.71 KCNH2 KCNE2
28 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.71 KCNQ1 KCNE2
29 positive regulation of potassium ion transmembrane transport GO:1901381 9.7 KCNQ1 KCNH2
30 calcium ion transport into cytosol GO:0060402 9.7 RYR2 CACNA1C
31 regulation of cardiac muscle cell contraction GO:0086004 9.7 SCN5A ANK2
32 cellular response to epinephrine stimulus GO:0071872 9.69 RYR2 KCNQ1
33 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.69 KCNQ1 KCNH2
34 SA node cell action potential GO:0086015 9.69 SCN5A SCN3B ANK2
35 regulation of sodium ion transmembrane transport GO:1902305 9.68 SCN5A RANGRF
36 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.68 RYR2 ANK2
37 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.68 SCN5A SCN3B
38 negative regulation of voltage-gated potassium channel activity GO:1903817 9.68 KCNQ1 KCNE2
39 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.67 PKP2 DSP
40 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.67 SCN5A KCNQ1
41 desmosome organization GO:0002934 9.67 PKP2 DSP
42 membrane depolarization during SA node cell action potential GO:0086046 9.66 SCN5A ANK2
43 membrane depolarization during AV node cell action potential GO:0086045 9.66 SCN5A CACNA1C
44 sarcoplasmic reticulum calcium ion transport GO:0070296 9.65 RYR2 ANK2
45 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.65 SCN5A CACNA1C
46 regulation of atrial cardiac muscle cell action potential GO:0098910 9.64 RYR2 ANK2
47 regulation of SA node cell action potential GO:0098907 9.64 RYR2 ANK2
48 membrane depolarization during Purkinje myocyte cell action potential GO:0086047 9.63 SCN5A SCN1B
49 cardiac muscle cell action potential involved in contraction GO:0086002 9.63 SCN5A SCN3B SCN1B PKP2 KCNE2 CACNA1C
50 ventricular cardiac muscle cell action potential GO:0086005 9.56 SCN5A SCN3B RYR2 PKP2 KCNQ1 KCNH2

Molecular functions related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.83 SCN5A RYR2 KCNQ1 CACNA1C
2 ion channel activity GO:0005216 9.8 SCN5A RYR2 KCNQ1 KCNH2 CACNA1C
3 potassium channel activity GO:0005267 9.73 KCNQ1 KCNH2 KCNE2
4 voltage-gated potassium channel activity GO:0005249 9.71 KCNQ1 KCNH2 KCNE2
5 scaffold protein binding GO:0097110 9.67 SCN5A KCNQ1 KCNH2 DSP
6 sodium channel activity GO:0005272 9.65 SCN5A SCN3B SCN1B
7 delayed rectifier potassium channel activity GO:0005251 9.63 KCNQ1 KCNH2 KCNE2
8 voltage-gated sodium channel activity GO:0005248 9.58 SCN5A SCN1B
9 inward rectifier potassium channel activity GO:0005242 9.58 KCNH2 KCNE2
10 protein kinase A catalytic subunit binding GO:0034236 9.57 RYR2 KCNQ1
11 sodium channel regulator activity GO:0017080 9.56 SCN3B SCN1B RANGRF PKP2
12 sodium channel inhibitor activity GO:0019871 9.55 SCN3B SCN1B
13 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.51 KCNQ1 KCNH2
14 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.5 KCNQ1 KCNH2 KCNE2
15 voltage-gated ion channel activity GO:0005244 9.5 SCN5A SCN3B SCN1B KCNQ1 KCNH2 KCNE2
16 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 9.49 PKP2 DSP
17 voltage-gated sodium channel activity involved in Purkinje myocyte action potential GO:0086062 9.43 SCN5A SCN1B
18 voltage-gated sodium channel activity involved in cardiac muscle cell action potential GO:0086006 9.33 SCN5A SCN3B SCN1B
19 ion channel binding GO:0044325 9.28 SCN5A SCN3B SCN1B RYR2 RANGRF PKP2

Sources for Cardiac Arrhythmia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....